Acorda Therapeutics, Inc. Nasdaq

Equities

ACOR

US00484M7002

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 12:25:03 17/07/2024 am IST			5-day change	1st Jan Change
0.2 ^USD	+53.85%		+11.11%	-98.67%

10/07	Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.	CI
03/07	Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.	CI

Acorda Therapeutics, Inc. Reports Unaudited Sales Results for the Fourth Quarter and Full Year of 2016; Provides Earnings Guidance for the Full Year of 2017

January 09, 2017 at 04:30 pm IST

Acorda Therapeutics, Inc. reported unaudited sales results for the fourth quarter and full year of 2016. For the quarter, the company reported net sales of $132 million.

For the full-year, net sales were $493 million, an increase of approximately 13% from 2015.

The company provided 2017 guidance for AMPYRA net sales of $535 to $545 million.

Latest news about Acorda Therapeutics, Inc.

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.	10/07	CI
Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.	03/07	CI
First Amended Joint Liquidation Plan and Disclosure Statement Filed by Acorda Therapeutics, Inc.	01/07	CI
Motion for Asset Sale Approved for Acorda Therapeutics, Inc.	12/06	CI
Acorda Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Liquidation Plan and Disclosure Statement Filed by Acorda Therapeutics, Inc.	10/05	CI
Final DIP Financing Approved for Acorda Therapeutics, Inc.	03/05	CI
Bidding Procedure Approved for Acorda Therapeutics, Inc.	29/04	CI
Acorda Therapeutics Delisted from Nasdaq, Now Trading on OTC Pink Market	16/04	MT
Interim DIP Financing Approved for Acorda Therapeutics, Inc.	05/04	CI
Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from S&P TMI Index	05/04	CI
Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.	01/04	CI
Transcript : Acorda Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023	09/23/09

Chart Acorda Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinsonâs disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+19.61%	126B
REGENERON PHARMACEUTICALS, INC.	+24.93%	118B
ARGENX SE	+24.69%	27.87B
BIONTECH SE	-16.74%	20.95B
GENMAB A/S	-14.80%	16.92B
BEIGENE, LTD.	-13.51%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+11.00%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+53.48%	14.08B

Bio Therapeutic Drugs